Triple-drug strategy eliminates pancreatic tumors in mice and prevents treatment resistance, study reports
Latest news on WhatsApp أجدد الأخبار على واتسابResearchers in Spain’s Spanish National Cancer Research Centre (CNIO) report that a targeted triple-drug regimen produced complete and durable tumor regressions in multiple mouse models of pancreatic ductal adenocarcinoma (PDAC), a disease known for rapid emergence of resistance to targeted therapies.
The approach was designed to block KRAS-driven signaling at three distinct “nodes,” rather than relying on a single target—an attempt to reduce the tumor’s ability to bypass therapy. The regimen combined daraxonrasib (a RAS(ON) inhibitor), afatinib (an EGFR-family tyrosine kinase inhibitor), and SD36 (a STAT3-targeting PROTAC degrader).
According to the reports, treated tumor-bearing mice underwent rapid tumor cell death and remained tumor-free for more than 200 days post-treatment, with the combination described as well tolerated in the animal studies.
Oncologists cautioned, however, that the findings are preclinical and cannot be applied to patient care without rigorously controlled human clinical trials. CNIO’s team also noted they are not yet in a position to move this exact triple combination directly into clinical testing.
In Canada, pancreatic cancer outcomes remain poor; the Canadian Cancer Society reports a 12% five-year net survival rate, underscoring the urgency for more effective treatment strategies.
